help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Georgopoulos, A.
Right arrow Articles by Tsai, M. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Georgopoulos, A.
Right arrow Articles by Tsai, M. Y.
The Journal of Clinical Endocrinology & Metabolism Vol. 87, No. 8 3735-3739
Copyright © 2002 by The Endocrine Society


Original Article

Unlike Type 2 Diabetes, Type 1 Does Not Interact with the Codon 54 Polymorphism of the Fatty Acid Binding Protein 2 Gene

Angeliki Georgopoulos, Omer Aras, Marina Noutsou and Michael Y. Tsai

Minneapolis Veterans Affairs Medical Center (A.G.), Departments of Medicine (A.G.) and Laboratory Medicine and Pathology (O.A., M.Y.T.), University of Minnesota, Minneapolis, Minnesota 55417; and the Second Department of Medicine (M.N.), Athens University Medical School, 115 27 Athens, Greece

Address all correspondence and requests for reprints to: Angeliki Georgopoulos, M.D., Medicine Service 111M, VAMC, One Veterans Drive, Minneapolis, Minnesota 55417. E-mail: . georg003{at}tc.umn.edu

Abstract

In type 2 diabetes, the threonine (Thr) for alanine (Ala) codon 54 polymorphism of the fatty acid binding protein 2 gene is associated with elevated fasting and postprandial triglycerides and dyslipidemia when compared with the wild type (Ala-54/Ala-54). To assess whether this is the case in patients with type 1 diabetes, who usually do not manifest the metabolic syndrome, we screened 181 patients with similar glycemic control as the type 2 patients. Thirty percent were heterozygous, and 9% were homozygous for the polymorphism. Mean (±SEM) fasting plasma triglyceride levels in patients with the wild type (n = 84), those heterozygous for Ala-54/Thr-54 (n = 44), and those homozygous for the Thr-54 (n = 13) were 1.0 ± 0.07, 1.1 ± 0.17, and 1.2 ± 0.23 mmol/liter, respectively. In addition, there were no differences in total, low-density lipoprotein, high-density lipoprotein, and non-high density lipoprotein cholesterol among the three groups. After a fat load, the postprandial area under the curve of triglyceride in plasma, chylomicrons, and very low-density lipoprotein were similar between the wild type (n = 18) and the Thr-54 homozygotes (n = 12). In conclusion, in contrast to type 2, type 1 diabetes does not interact with the codon 54 polymorphism of the fatty acid binding protein 2 gene to cause hypertriglyceridemia/dyslipidemia. Insulin resistance could account possibly for this difference.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society